Kymera Results Presentation Deck

Tumor Volume (mm³) Mean, +SEM KT-333 Highly Active on Intermittent Dosing Regimens Complete Tumor Regressions Associated with Robust STAT3 KD for ~48h in Preclinical Models 3000 2000 1000- 0 SU-DHL-1 Weekly Dosing Vehicle KT-333, 5 mg/kg, QW KT-333, 10 mg/kg, QW [ITHH HH 10 5 15 Days (Post-randomization) HH 20 KYMERA ©2022 KYMERA THERAPEUTICS, INC. 25 Dose- and degradation-dependent tumor growth inhibition observed with once-weekly dosing in ALK+ ALCL 10 mg/kg sufficient to drive full tumor regression in SU-DHL- 1 that was durable for multiple weeks after the last dose (on day 14) 100000 KT-333 Concentration (ng/ml or ng/g) 10000 1000 100 10 Preclinical PK/PD •Tumor PK 48 Plasma PK 96 Time (hr) 144 Tumor PD 192 240 150 100 50 -0 Based on preclinical model (STAT3 dependent ALK+ ALCL), target PD >90% STAT3 KD for ~48 hours to achieve robust anti-tumor activity % of Vehicle Control PAGE 9

View entire presentation